Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniela Russo

Showing results (201-210 of 209) with videos related to

Pageof 21
Sort By:
You have reached the last page of results.This site can display upto 209 results.
Journal of Experimental & Clinical Cancer Research : CR|April 11, 2023
Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the phase IV ovarian cancer MITO-16A/MANGO-OV2A trialLuca Forlani, Loris De Cecco, Vittorio Simeon, et al.
NPJ Precision Oncology|November 17, 2025
Tumour-infiltrating leucocytes as prognostic biomarkers of bevacizumab-treated ovarian cancer patients results from the phase IV MITO16A/MaNGO OV-2 clinical trialEliana Pivetta, Vincenzo Canzonieri, Marina Bagnoli, et al.
Cancers|April 12, 2022
Biological Role of Tumor/Stromal CXCR4-CXCL12-CXCR7 in MITO16A/MaNGO-OV2 Advanced Ovarian Cancer PatientsCrescenzo D'Alterio, Anna Spina, Laura Arenare, et al.
Cancer Research Communications|December 19, 2025
CCDC6 immunostaining in conjunction with the Rad51 HRD assay may expand PARPi treatment eligibility in HGSOC patientsDaniela Criscuolo, Francesco Merolla, Benedetta Pellegrino, et al.
The Lancet. Oncology|July 13, 2016
Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort studyMarina Bagnoli, Silvana Canevari, Daniela Califano, et al.
British Journal of Cancer|July 22, 2022
Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22)Lucia Musacchio, Daniela Califano, Michele Bartoletti, et al.
Science Advances|January 15, 2025
CD4<sup>+</sup>FOXP3Exon2<sup>+</sup> regulatory T cell frequency predicts breast cancer prognosis and survivalClorinda Fusco, Francesca Di Rella, Antonietta Liotti, et al.
The Lancet. Oncology|April 13, 2023
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trialSandro Pignata, Giovanni Scambia, Clorinda Schettino, et al.
Cancers|October 23, 2021
Evaluation of Angiogenesis-Related Genes as Prognostic Biomarkers of Bevacizumab Treated Ovarian Cancer Patients: Results from the Phase IV MITO16A/ManGO OV-2 Translational StudyDaniela Califano, Daniela Gallo, Gian Luca Rampioni Vinciguerra, et al.
Pageof 21

Showing results (201-210 of 209) with videos related to

Sort By:
Pageof 21
You have reached the last page of results.This site can display upto 209 results.
Journal of Experimental & Clinical Cancer Research : CR|April 11, 2023
Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the phase IV ovarian cancer MITO-16A/MANGO-OV2A trialLuca Forlani, Loris De Cecco, Vittorio Simeon, et al.
NPJ Precision Oncology|November 17, 2025
Tumour-infiltrating leucocytes as prognostic biomarkers of bevacizumab-treated ovarian cancer patients results from the phase IV MITO16A/MaNGO OV-2 clinical trialEliana Pivetta, Vincenzo Canzonieri, Marina Bagnoli, et al.
Cancers|April 12, 2022
Biological Role of Tumor/Stromal CXCR4-CXCL12-CXCR7 in MITO16A/MaNGO-OV2 Advanced Ovarian Cancer PatientsCrescenzo D'Alterio, Anna Spina, Laura Arenare, et al.
Cancer Research Communications|December 19, 2025
CCDC6 immunostaining in conjunction with the Rad51 HRD assay may expand PARPi treatment eligibility in HGSOC patientsDaniela Criscuolo, Francesco Merolla, Benedetta Pellegrino, et al.
The Lancet. Oncology|July 13, 2016
Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort studyMarina Bagnoli, Silvana Canevari, Daniela Califano, et al.
British Journal of Cancer|July 22, 2022
Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22)Lucia Musacchio, Daniela Califano, Michele Bartoletti, et al.
Science Advances|January 15, 2025
CD4<sup>+</sup>FOXP3Exon2<sup>+</sup> regulatory T cell frequency predicts breast cancer prognosis and survivalClorinda Fusco, Francesca Di Rella, Antonietta Liotti, et al.
The Lancet. Oncology|April 13, 2023
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trialSandro Pignata, Giovanni Scambia, Clorinda Schettino, et al.
Cancers|October 23, 2021
Evaluation of Angiogenesis-Related Genes as Prognostic Biomarkers of Bevacizumab Treated Ovarian Cancer Patients: Results from the Phase IV MITO16A/ManGO OV-2 Translational StudyDaniela Califano, Daniela Gallo, Gian Luca Rampioni Vinciguerra, et al.
Pageof 21